



ANUPAM RASAYAN INDIA LTD.

ARILSLDSTX20260523015

Date: May 23, 2026

To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001, India SCRIP CODE: 543275	To, National Stock Exchange of India Limited 'Exchange Plaza', C-1, Block-G, Bandra Kurla Complex, Bandra (East), Mumbai-400051, India SYMBOL: ANURAS
---	--

Dear Sir/Madam,

Subject: Intimation of Press Release.

Pursuant to Regulation 30 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release to be issued by Anupam Rasayan India Limited today i.e., May 23, 2026, titled "Anupam Rasayan India Limited enters into a definitive agreement to acquire 43.3-48.2% equity stake + Open Offer to the public shareholders of Bliss GVS Pharma Limited"

This Press Release will also be hosted on the website of the Company at www.anupamrasayan.com.

We request you to kindly take note the same.

Thanking you,

Yours Faithfully,

For Anupam Rasayan India Limited

Anand Desai
Managing Director
DIN: 00038442

Encl: As above



ANUPAM RASAYAN INDIA LTD.

Anupam Rasayan India Limited

Press Release

Anupam Rasayan India Limited enters into a definitive agreement to acquire 43.3-48.2% equity stake + Open Offer to the public shareholders of Bliss GVS Pharma Limited

Surat, May 23rd 2026: Anupam Rasayan India Ltd. (NSE: ANURAS, BSE: 543275), a leading provider of custom synthesis and specialty chemicals, today announced acquisition of 43.3-48.2% equity stake + Open Offer to the public shareholders of Bliss GVS Pharma Limited (NSE: BLISSGVS, BSE: 506197), an India-based pharmaceutical formulations company.

The total purchase consideration has been financed through:

- Rs 300 Crores via Term Loan
- Non-Controlling non-voting equity instrument for the balance amount

About Bliss GVS Pharma Limited:

Bliss GVS Pharma Limited is an India-based pharmaceutical formulations company engaged in the development, manufacturing, marketing, and export of a wide range of dosage forms including suppositories, pessaries, tablets, capsules, syrups, injectables, creams, and ointments. Established in 1984 and listed on the NSE and BSE, the company has built a strong presence across regulated and semi-regulated international markets, particularly in Africa, Asia, and Latin America.

The company is globally recognized for its leadership in suppositories and pessaries, with one of the largest product portfolios in this segment and being among the few EU-GMP certified manufacturers in India. Bliss GVS Pharma has a diversified portfolio of over 150 branded formulations across therapeutic areas such as anti-malarial, anti-fungal, anti-bacterial, anti-inflammatory, and women's healthcare. Key brands such as Lonart, P-Alaxin, Funbact, and Lofnac are well-established and hold strong leadership positions across their respective markets.

The company operates multiple manufacturing facilities in Maharashtra and Daman with approvals from US FDA, WHO-GMP and EU-GMP. The company has developed strong capabilities in niche dosage forms and continues to expand its R&D, manufacturing, and international marketing footprint to drive long-term growth.

Commenting on the acquisition, Mr. Anand Desai, Managing Director, Anupam Rasayan India Ltd., said "We are pleased to inform that we have entered into a definitive agreement to acquire 43.3%-48.2% equity stake and are making an Open Offer to the public shareholders of Bliss GVS Pharma Limited, marking another important milestone in Anupam Rasayan's vision of building an integrated global life sciences and specialty pharmaceutical platform.

This will strategically strengthen our presence across the pharmaceutical value chain, spanning KSMs to finished dosage formulations. Bliss GVS Pharma brings well-established capabilities in niche dosage forms, a strong international footprint, differentiated brands, and expertise across multiple therapeutic segments.

Together with Anupam Rasayan's advanced chemistry capabilities, the combined platform would create a broader integrated and diversified pharmaceutical manufacturing ecosystem with deeper backward integration,

enhanced global reach especially in the Europe and America market, further strengthen by Jayhawk acquisition. We believe this will unlock significant synergies through expanded product offerings, stronger regulated market presence, improved customer engagement, and accelerated innovation across regulated and semi-regulated markets.

This integrated platform approach further reinforces our long-term growth strategy and positions us well to drive sustainable growth, operational efficiencies, and long-term value creation for all stakeholders.”

About Anupam Rasayan India Limited

Anupam Rasayan India Ltd (Anupam) is one of the leading companies engaged in the custom synthesis (CSM) and manufacturing of specialty chemicals in India. Incorporated in 1984, the specialty chemicals major has two verticals: Life science related Specialty Chemicals comprising products related to Agrochemicals, Personal Care and Pharmaceuticals, Other Specialty Chemicals comprising Polymer Additives. Anupam caters to a diverse base of Indian and global customers. It is currently manufacturing products for over 185+ domestic and international customers. Anupam operates via its eight manufacturing facilities, with six facilities located in Gujarat, one in Tamil Nadu and one in U.S. with an aggregate installed capacity of ~2,00,000+ MT as of March 31, 2026. Anupam offers multistep synthesis and undertakes complex chemical reactions technologies, for a diverse base of Indian and global customers.

For more information, please contact:

<u>Company Details</u>	<u>Investor Relations Advisors</u>
<p><u>Anupam Rasayan India Ltd.</u></p>  <p>CIN: L24231GJ2003PLC042988 www.anupamrasayan.com</p>	<p><u>Strategic Growth Advisors Pvt. Ltd.</u></p> <p>SGA <u>Strategic Growth Advisors</u></p> <p>CIN - U74140MH2010PTC204285 Mr. Shrikant Sangani / Ms. Shaily Patwa Email - shrikant.sangani@sgapl.net / shaily.p@sgapl.net Mobile No – 9619595686 / 9819494608 www.sgapl.net</p>

DISCLAIMER:

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Anupam Rasayan India Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.